CN1289081C - 改进释放的胰岛素致敏物的药用组合物 - Google Patents

改进释放的胰岛素致敏物的药用组合物 Download PDF

Info

Publication number
CN1289081C
CN1289081C CNB998154946A CN99815494A CN1289081C CN 1289081 C CN1289081 C CN 1289081C CN B998154946 A CNB998154946 A CN B998154946A CN 99815494 A CN99815494 A CN 99815494A CN 1289081 C CN1289081 C CN 1289081C
Authority
CN
China
Prior art keywords
chemical compound
release
thiazolidine
diketone
benzyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CNB998154946A
Other languages
English (en)
Chinese (zh)
Other versions
CN1333683A (zh
Inventor
R·格利尼克
S·M·米洛索维克
W·穆尔多恩
V·雷
J·绍尔
J·L·斯金纳
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
SmithKline Beecham Ltd
SmithKline Beecham Corp
Original Assignee
SmithKline Beecham Ltd
SmithKline Beecham Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9824870.1A external-priority patent/GB9824870D0/en
Priority claimed from GBGB9912189.9A external-priority patent/GB9912189D0/en
Application filed by SmithKline Beecham Ltd, SmithKline Beecham Corp filed Critical SmithKline Beecham Ltd
Publication of CN1333683A publication Critical patent/CN1333683A/zh
Application granted granted Critical
Publication of CN1289081C publication Critical patent/CN1289081C/zh
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005Wall or coating material
    • A61K9/5021Organic macromolecular compounds
    • A61K9/5026Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/335Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/3533,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2022Organic macromolecular compounds
    • A61K9/2027Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/28Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806Coating materials
    • A61K9/2833Organic macromolecular compounds
    • A61K9/284Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A61K9/2846Poly(meth)acrylates
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A61K9/5078Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Organic Chemistry (AREA)
  • Obesity (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CNB998154946A 1998-11-12 1999-11-12 改进释放的胰岛素致敏物的药用组合物 Expired - Fee Related CN1289081C (zh)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
GBGB9824870.1A GB9824870D0 (en) 1998-11-12 1998-11-12 Novel composition and use
GB9824870.1 1998-11-12
GB9912189.9 1999-05-25
GBGB9912189.9A GB9912189D0 (en) 1999-05-25 1999-05-25 Novel composition and use

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN 200610137413 Division CN1935125A (zh) 1998-11-12 1999-11-12 改进释放的胰岛素致敏物的药用组合物

Publications (2)

Publication Number Publication Date
CN1333683A CN1333683A (zh) 2002-01-30
CN1289081C true CN1289081C (zh) 2006-12-13

Family

ID=26314667

Family Applications (1)

Application Number Title Priority Date Filing Date
CNB998154946A Expired - Fee Related CN1289081C (zh) 1998-11-12 1999-11-12 改进释放的胰岛素致敏物的药用组合物

Country Status (39)

Country Link
EP (3) EP1815855A1 (pt)
JP (1) JP2002529505A (pt)
KR (2) KR20060097140A (pt)
CN (1) CN1289081C (pt)
AP (2) AP2008004490A0 (pt)
AR (2) AR023699A1 (pt)
AT (1) ATE382352T1 (pt)
AU (1) AU768578B2 (pt)
BG (2) BG109893A (pt)
BR (1) BR9915215A (pt)
CA (1) CA2350659C (pt)
CO (1) CO5190673A1 (pt)
CY (1) CY1107909T1 (pt)
CZ (1) CZ20011628A3 (pt)
DE (1) DE69937898T2 (pt)
DK (1) DK1128827T3 (pt)
DZ (1) DZ2937A1 (pt)
EA (3) EA200702648A1 (pt)
EG (2) EG22344A (pt)
ES (1) ES2299269T3 (pt)
HK (1) HK1040909B (pt)
HR (2) HRP20010342B1 (pt)
HU (1) HUP0104307A3 (pt)
ID (1) ID29344A (pt)
IL (2) IL143003A0 (pt)
MY (1) MY135973A (pt)
NO (1) NO20012351L (pt)
NZ (2) NZ526440A (pt)
OA (1) OA11676A (pt)
PE (1) PE20001428A1 (pt)
PL (1) PL198717B1 (pt)
PT (1) PT1128827E (pt)
RS (1) RS50208B (pt)
SI (1) SI1128827T1 (pt)
SK (1) SK286937B6 (pt)
TR (2) TR200503846T2 (pt)
TW (2) TWI257305B (pt)
UY (2) UY25798A1 (pt)
WO (1) WO2000028990A1 (pt)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6099862A (en) * 1998-08-31 2000-08-08 Andrx Corporation Oral dosage form for the controlled release of a biguanide and sulfonylurea
MY125516A (en) 1999-11-16 2006-08-30 Smithkline Beecham Plc Novel composition based on thiazolidinedione and metformin and use
WO2001051008A2 (en) * 2000-01-07 2001-07-19 University Of Cincinnati Selective activation of a th1 or th2 lymphocyte regulated immune response
PL201766B1 (pl) * 2001-01-31 2009-05-29 Roehm Gmbh Wielocząsteczkowa postać leku zawierająca przynajmniej dwa typy granulek powlekanych w odmienny sposób oraz jej zastosowanie
ES2259736T3 (es) * 2001-12-21 2006-10-16 Smithkline Beecham Corporation Regimen de dosificacion para activadores de ppar-gamma-.
PE20030800A1 (es) * 2002-02-12 2003-10-31 Glaxo Group Ltd Forma de dosificacion oral de liberacion controlada
AU2003281181A1 (en) * 2002-07-11 2004-02-02 Takeda Pharmaceutical Company Limited Process for producing coated preparation
US7018658B2 (en) * 2002-11-14 2006-03-28 Synthon Bv Pharmaceutical pellets comprising tamsulosin
ES2645930T3 (es) 2003-01-03 2017-12-11 Supernus Pharmaceuticals, Inc. Utilización de una mezcla de dos o más materiales entéricos para regular la liberación de fármacos a través de una membrana o matriz para terapias sistémicas
EP1588708A4 (en) 2003-01-29 2006-03-01 Takeda Pharmaceutical METHOD FOR PRODUCING COATED PREPARATION
ES2241478B1 (es) * 2004-02-13 2006-11-16 Lacer S.A. Preparacion farmaceutica para la liberacion sostenida de un principio farmaceuticamente activo.
FI20060501L (fi) * 2006-05-22 2007-11-23 Biohit Oyj Koostumus ja menetelmä asetaldehydin sitomiseksi vatsassa
WO2013010137A2 (en) * 2011-07-14 2013-01-17 Jacks Health Technologies Llc A composition, device and method for delayed and sustained release of brain energy molecules
CA2902911C (en) 2014-10-31 2017-06-27 Purdue Pharma Methods and compositions particularly for treatment of attention deficit disorder
US10722473B2 (en) 2018-11-19 2020-07-28 Purdue Pharma L.P. Methods and compositions particularly for treatment of attention deficit disorder

Family Cites Families (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5522636A (en) 1978-08-04 1980-02-18 Takeda Chem Ind Ltd Thiazoliding derivative
JPS5697277A (en) 1980-01-07 1981-08-05 Takeda Chem Ind Ltd Thiazolidine derivative
JPS6051189A (ja) 1983-08-30 1985-03-22 Sankyo Co Ltd チアゾリジン誘導体およびその製造法
US4582839A (en) 1984-03-21 1986-04-15 Takeda Chemical Industries, Ltd. 2,4-thiazolidinediones
CN1003445B (zh) 1984-10-03 1989-03-01 武田药品工业株式会社 噻唑烷二酮衍生物,其制备方法和用途
DK173350B1 (da) 1985-02-26 2000-08-07 Sankyo Co Thiazolidinderivater, deres fremstilling og farmaceutisk paæparat indeholdende dem
JPH06779B2 (ja) 1985-06-10 1994-01-05 武田薬品工業株式会社 チアゾリジオン誘導体およびそれを含んでなる医薬組成物
US4812570A (en) 1986-07-24 1989-03-14 Takeda Chemical Industries, Ltd. Method for producing thiazolidinedione derivatives
EP0842925A1 (en) * 1987-09-04 1998-05-20 Beecham Group Plc Substituted thiazolidinedione derivatives
US4791125A (en) 1987-12-02 1988-12-13 Pfizer Inc. Thiazolidinediones as hypoglycemic and anti-atherosclerosis agents
WO1989008650A1 (en) 1988-03-08 1989-09-21 Pfizer Inc. Thiazolidinedione hypoglycemic agents
MX15171A (es) 1988-03-08 1993-05-01 Pfizer Derivados de tiazolidinodiona hipoglicemicos
WO1991007107A1 (en) 1989-11-13 1991-05-30 Pfizer Inc. Oxazolidinedione hypoglycemic agents
US5089514A (en) 1990-06-14 1992-02-18 Pfizer Inc. 3-coxazolyl [phenyl, chromanyl or benzofuranyl]-2-hydroxypropionic acid derivatives and analogs as hypoglycemic agents
CA2086606A1 (en) 1990-07-03 1992-01-04 Kunihiro Niigata Bisheterocyclic compound
ATE116971T1 (de) 1990-08-23 1995-01-15 Pfizer Hypoglykämische hydroxyharnstoffderivate.
JPH04210683A (ja) 1990-12-06 1992-07-31 Terumo Corp チアゾリジン−2,4−ジオン誘導体およびこれを含有する糖尿病合併症治療薬
DE69231886T2 (de) 1991-04-11 2002-03-28 Upjohn Co Thiazolidindionderivate, herstellung und anwendung
US5183823A (en) 1991-04-11 1993-02-02 Takeda Chemical Industries, Ltd. Pyridine n-oxide compounds which are useful as hypoglycemic and hypolipidemic agents
US5502078A (en) * 1991-05-28 1996-03-26 Zeneca Limited Chemical compounds
TW222626B (pt) 1991-07-22 1994-04-21 Pfizer
FR2680512B1 (fr) 1991-08-20 1995-01-20 Adir Nouveaux derives de 2,4-thiazolidinedione, leur procede de preparation et les compositions pharmaceutiques qui les contiennent.
JPH05271204A (ja) 1992-03-26 1993-10-19 Japan Tobacco Inc 新規なトリアジン誘導体
US5264451A (en) 1992-04-07 1993-11-23 American Home Products Corporation Process for treating hyperglycemia using trifluoromethyl substituted 3H-pyrazol-3-ones
WO1993021166A1 (en) 1992-04-10 1993-10-28 Smithkline Beecham Plc Heterocyclic compounds and their use in the treatment of type ii-diabetes
WO1993022445A1 (en) 1992-05-05 1993-11-11 The Upjohn Company A process for producing pioglitazone metabolite
WO1994001420A1 (en) 1992-07-03 1994-01-20 Smithkline Beecham Plc Heterocyclic compounds as pharmaceutical
US5326770A (en) * 1992-07-17 1994-07-05 The Du Pont Merck Pharmaceutical Company Monoamine oxidase-B (MAO-B) inhibitory 5-substituted 2,4-thiazolidinediones useful in treating memory disorders of mammals
US5232945A (en) 1992-07-20 1993-08-03 Pfizer Inc. 3-aryl-2-hydroxypropionic acid derivatives and analogs as antihypertensives
GB9218830D0 (en) * 1992-09-05 1992-10-21 Smithkline Beecham Plc Novel compounds
US5478852C1 (en) 1993-09-15 2001-03-13 Sankyo Co Use of thiazolidinedione derivatives and related antihyperglycemic agents in the treatment of impaired glucose tolerance in order to prevent or delay the onset of noninsulin-dependent diabetes mellitus
DE4432757A1 (de) * 1994-09-14 1996-03-21 Boehringer Mannheim Gmbh Pharmazeutische Zubereitung enthaltend Metformin und Verfahren zu deren Herstellung
TWI238064B (en) * 1995-06-20 2005-08-21 Takeda Chemical Industries Ltd A pharmaceutical composition for prophylaxis and treatment of diabetes
US5840332A (en) * 1996-01-18 1998-11-24 Perio Products Ltd. Gastrointestinal drug delivery system
JP3256841B2 (ja) * 1996-06-27 2002-02-18 武田薬品工業株式会社 ベンズアルデヒド化合物の製造法
US5952509A (en) * 1996-06-27 1999-09-14 Takeda Chemical Industries, Ltd. Production of benzaldehyde compounds
GB9619757D0 (en) * 1996-09-21 1996-11-06 Knoll Ag Chemical process
AU6576398A (en) * 1997-03-24 1998-10-20 Galderma Research & Development, S.N.C. Retinoid related molecules for the treatment of non-insulin dependent diabetes mellitus

Also Published As

Publication number Publication date
PT1128827E (pt) 2008-03-10
EG24463A (en) 2009-07-16
HRP20010342A2 (en) 2002-06-30
KR20010073229A (ko) 2001-07-31
HRP20010342B1 (en) 2008-04-30
DE69937898T2 (de) 2009-01-02
AU1272900A (en) 2000-06-05
DK1128827T3 (da) 2008-04-28
UY25798A1 (es) 2000-12-29
BG65444B1 (bg) 2008-08-29
HK1040909A1 (en) 2002-06-28
TW200505436A (en) 2005-02-16
CN1333683A (zh) 2002-01-30
BG105570A (en) 2002-02-28
CA2350659C (en) 2009-06-09
NZ526440A (en) 2005-01-28
EP1128827A1 (en) 2001-09-05
ATE382352T1 (de) 2008-01-15
SK6432001A3 (en) 2001-12-03
EA200702648A1 (ru) 2008-10-30
AR023700A1 (es) 2002-09-04
TR200503846T2 (tr) 2007-01-22
AR023699A1 (es) 2002-09-04
HK1040909B (zh) 2008-08-01
NO20012351D0 (no) 2001-05-11
NZ511611A (en) 2003-10-31
EP1815855A1 (en) 2007-08-08
AP1901A (en) 2008-10-24
CA2350659A1 (en) 2000-05-25
CO5190673A1 (es) 2002-08-29
DE69937898D1 (de) 2008-02-14
EP1128827B1 (en) 2008-01-02
PE20001428A1 (es) 2001-02-08
EP1917962A1 (en) 2008-05-07
EA007608B1 (ru) 2006-12-29
MY135973A (en) 2008-07-31
BR9915215A (pt) 2001-07-31
CZ20011628A3 (cs) 2001-12-12
HUP0104307A2 (hu) 2002-07-29
OA11676A (en) 2005-01-12
TR200101337T2 (tr) 2001-11-21
EG22344A (en) 2002-12-31
ID29344A (id) 2001-08-23
WO2000028990A1 (en) 2000-05-25
PL348153A1 (en) 2002-05-06
EA200601144A1 (ru) 2007-02-27
TWI246920B (en) 2006-01-11
CY1107909T1 (el) 2013-09-04
SI1128827T1 (sl) 2008-06-30
HRP20080117A2 (en) 2008-10-31
AU768578B2 (en) 2003-12-18
JP2002529505A (ja) 2002-09-10
AP2008004490A0 (en) 2008-06-30
UY25800A1 (es) 2000-08-21
SK286937B6 (sk) 2009-07-06
IL143003A0 (en) 2002-04-21
EA200100540A1 (ru) 2001-10-22
PL198717B1 (pl) 2008-07-31
KR20060097140A (ko) 2006-09-13
BG109893A (bg) 2008-11-28
IL183972A0 (en) 2007-10-31
NO20012351L (no) 2001-07-04
HUP0104307A3 (en) 2003-12-29
DZ2937A1 (fr) 2004-03-15
YU36401A (sh) 2004-05-12
ES2299269T3 (es) 2008-05-16
KR100732599B1 (ko) 2007-06-27
RS50208B (sr) 2009-07-15
TWI257305B (en) 2006-07-01

Similar Documents

Publication Publication Date Title
CN1289081C (zh) 改进释放的胰岛素致敏物的药用组合物
CN1117567C (zh) 帕罗西汀控释组合物
CN1089584C (zh) 动脉硬化和黄瘤的治疗
CN100341493C (zh) 用于延时和受控释放药物活性成分的微粒口服盖仑制剂
CN1227002C (zh) 包含聚醋酸乙烯酯和聚乙烯基吡咯烷酮的含活性成分漂浮形式及其用途与制备
CN1348369A (zh) 改进释放胰岛素致敏剂和另一抗糖尿病药的药用组合物
US20070281023A1 (en) Pharmaceutical composition for modified release insulin sensitiser
CN1443068A (zh) 用于治疗糖尿病的二肽基肽酶iv抑制剂和其它抗糖尿病药剂的组合用药物
CN1976682A (zh) 用于延时和控制释放药物活性成分的微粒口服盖仑制剂
CN1893929A (zh) 缓释文拉法辛药物制剂
CN1615124A (zh) 配方
CN1874767A (zh) 包含aplindore和其衍生物的缓释药物组合物
CN1112926C (zh) 含有5-[4-[2-(n-甲基-n-2-吡啶基)氨基)乙氧基]苄基]噻唑烷-2,4-二酮的组合物
CN1832729A (zh) 长时间释放弱碱的组合物
CN1499961A (zh) 一种在胃液中漂浮并多脉冲释放活性物质的药用片剂系统、该系统和该系统包封物的制备方法
CN1168451C (zh) 噻唑烷二酮和磺酰脲组合物在制备治疗糖尿病的药物中的用途
CN1264302A (zh) 用噻唑烷二酮和磺酰脲治疗糖尿病
CN1874772A (zh) 治疗隐匿性胃食管反流的咪唑并[1,2-a]吡啶衍生物
CN1551778A (zh) 用于糖尿病神经病变的药物组合物
CN1935125A (zh) 改进释放的胰岛素致敏物的药用组合物
CN1665499A (zh) 用于预防或抑制糖尿病并发症发展的药物组合物
CN101057837A (zh) 一种右旋酮洛芬肠溶微丸及制备方法
CN1891296A (zh) 含有钙拮抗剂和苯氧酸类化合物的药物组合物
AU2004233487A1 (en) Pharmaceutical composition for modified release insulin sensitiser
AU2008202896A1 (en) Pharmaceutical composition for modified release insulin sensitiser

Legal Events

Date Code Title Description
C06 Publication
C10 Entry into substantive examination
PB01 Publication
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
C17 Cessation of patent right
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20061213

Termination date: 20101112